TOP TEN perturbations for 38877_s_at (Homo sapiens)
Organism: Homo sapiens
Gene: 38877_s_at
Selected probe(set): 239144_at
Platform: Affymetrix Human Genome U133 Plus 2.0 Array
Expression of 38877_s_at (239144_at) across 6674 perturbations tested by GENEVESTIGATOR:
CNS cancer study 1 (PDX; glioma, malignant, NOS; primary) / CNS cancer study 1 (PDX; ependymoma, NOS; primary)
Relative Expression (log2-ratio):-6.3618364Number of Samples:2 / 2
| Experimental | CNS cancer study 1 (PDX; glioma, malignant, NOS; primary) |
| Patient-derived xenograft (PDX) samples generated in female athymic nude mice from patients with primary glioma, malignant, NOS of the central nervous system (subcutaneously implanted). | |
| Control | CNS cancer study 1 (PDX; ependymoma, NOS; primary) |
| Patient-derived xenograft (PDX) samples generated in female athymic nude mice from patients with primary ependymoma, NOS of the central nervous system (subcutaneously implanted). |
CNS cancer study 1 (PDX; glioma, malignant, NOS; primary) / CNS cancer study 1 (PDX; glioblastoma, NOS; primary)
Relative Expression (log2-ratio):-5.157625Number of Samples:2 / 3
| Experimental | CNS cancer study 1 (PDX; glioma, malignant, NOS; primary) |
| Patient-derived xenograft (PDX) samples generated in female athymic nude mice from patients with primary glioma, malignant, NOS of the central nervous system (subcutaneously implanted). | |
| Control | CNS cancer study 1 (PDX; glioblastoma, NOS; primary) |
| Patient-derived xenograft (PDX) samples generated in female athymic nude mice from patients with primary glioblastoma, NOS of the central nervous system (subcutaneously implanted). |
glioma study 17 (small cell glioblastoma; A2B5+) / non-tumor oligodendrocyte progenitor cell sample (cortex)
Relative Expression (log2-ratio):-3.4633465Number of Samples:2 / 3
| Experimental | glioma study 17 (small cell glioblastoma; A2B5+) |
| Oligodendrocyte progenitor cells (OPC) isolated from high grade small cell glioblastoma (grade IV). OPC were isolated using magnetic-activated cell sorting (MACS) with antibodies against A2B5 antigen. Patients were 56 ± 3 years old males. | |
| Control | non-tumor oligodendrocyte progenitor cell sample (cortex) |
| Oligodendrocyte progenitor cells (OPC) isolated from cortical tissue, which was obtained from patients with epilepsy, but without any manifested brain cancer. OPC were isolated using magnetic-activated cell sorting (MACS) with antibodies against A2B5 antigen. |
endometrial cancer study 1 (PDX; carcinosarcoma, NOS; metastatic) / endometrial cancer study 1 (PDX; adenocarcinoma, NOS; metastatic)
Relative Expression (log2-ratio):3.2174177Number of Samples:3 / 2
| Experimental | endometrial cancer study 1 (PDX; carcinosarcoma, NOS; metastatic) |
| Patient-derived xenograft (PDX) samples generated in female athymic nude mice from a metastasis of patients with primary carcinosarcoma, NOS of the endometrium (subcutaneously implanted). Metastatic site of patient tumor sample is not reported. | |
| Control | endometrial cancer study 1 (PDX; adenocarcinoma, NOS; metastatic) |
| Patient-derived xenograft (PDX) samples generated in female athymic nude mice from a metastasis of patients with primary adenocarcinoma, NOS of the endometrium (subcutaneously implanted). Metastatic site of patient tumor sample is not reported. |
glioma study 17 (oligodendroglioma; A2B5+) / non-tumor oligodendrocyte progenitor cell sample (cortex)
Relative Expression (log2-ratio):-3.1471825Number of Samples:3 / 3
| Experimental | glioma study 17 (oligodendroglioma; A2B5+) |
| Oligodendrocyte progenitor cells (OPC) isolated from low grade oligodendroglioma (grade II). OPC were isolated using magnetic-activated cell sorting (MACS) with antibodies against A2B5 antigen. Patients were 39 ± 9 years old. | |
| Control | non-tumor oligodendrocyte progenitor cell sample (cortex) |
| Oligodendrocyte progenitor cells (OPC) isolated from cortical tissue, which was obtained from patients with epilepsy, but without any manifested brain cancer. OPC were isolated using magnetic-activated cell sorting (MACS) with antibodies against A2B5 antigen. |
endometrial cancer study 1 (PDX; carcinosarcoma, NOS; metastatic) / endometrial cancer study 1 (PDX; carcinosarcoma, NOS; primary)
Relative Expression (log2-ratio):3.1452875Number of Samples:3 / 10
| Experimental | endometrial cancer study 1 (PDX; carcinosarcoma, NOS; metastatic) |
| Patient-derived xenograft (PDX) samples generated in female athymic nude mice from a metastasis of patients with primary carcinosarcoma, NOS of the endometrium (subcutaneously implanted). Metastatic site of patient tumor sample is not reported. | |
| Control | endometrial cancer study 1 (PDX; carcinosarcoma, NOS; primary) |
| Patient-derived xenograft (PDX) samples generated in female athymic nude mice from patients with primary carcinosarcoma, NOS of the endometrium (subcutaneously implanted). |
glioma study 17 (anaplastic astrocytoma; A2B5+) / non-tumor oligodendrocyte progenitor cell sample (cortex)
Relative Expression (log2-ratio):-2.9550762Number of Samples:2 / 3
| Experimental | glioma study 17 (anaplastic astrocytoma; A2B5+) |
| Oligodendrocyte progenitor cells (OPC) isolated from high grade anaplastic astrocytoma (grade III). OPC were isolated using magnetic-activated cell sorting (MACS) with antibodies against A2B5 antigen. Patients were 45 ± 18 years old. | |
| Control | non-tumor oligodendrocyte progenitor cell sample (cortex) |
| Oligodendrocyte progenitor cells (OPC) isolated from cortical tissue, which was obtained from patients with epilepsy, but without any manifested brain cancer. OPC were isolated using magnetic-activated cell sorting (MACS) with antibodies against A2B5 antigen. |
brain tumor study 1 (pilocytic astrocytoma) / brain tumor study 1 (medulloblastoma)
Relative Expression (log2-ratio):2.8273Number of Samples:15 / 22
| Experimental | brain tumor study 1 (pilocytic astrocytoma) |
| Primary tumor tissue sample from the brain of patients with pilocytic astrocytoma. | |
| Control | brain tumor study 1 (medulloblastoma) |
| Primary tumor tissue sample from the brain of patients with medulloblastoma. |
glioma study 27 (astrocytoma, anaplastic) / glioma study 27 (astrocytoma, NOS)
Relative Expression (log2-ratio):-2.7875423Number of Samples:6 / 5
| Experimental | glioma study 27 (astrocytoma, anaplastic) |
| Primary tumor samples from resected brain tissues of patients with anaplastic astrocytoma(WHO grade III astrocytoma). | |
| Control | glioma study 27 (astrocytoma, NOS) |
| Primary tumor samples from resected brain tissues of patients with astrocytoma, NOS (WHO grade II astrocytoma). |
brain tumor study 1 (medulloblastoma) / normal brain tissue
Relative Expression (log2-ratio):-2.774396Number of Samples:22 / 12
| Experimental | brain tumor study 1 (medulloblastoma) |
| Primary tumor tissue sample from the brain of patients with medulloblastoma. | |
| Control | normal brain tissue |
| Histologically normal and non-neoplastic tissue sample from different brain anatomical sites of patients with primary brain tumors. |